Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Stability of Fagron's Phytobase Cream Compounded with Various Hormones

Author(s):  Wynn Tom, Taylor Sarah, Zander Clark

Issue:  Mar/Apr 2021 - Volume 25, Number 2
View All Articles in Issue

Page(s):  156-162

Stability of Fagron's Phytobase Cream Compounded with Various Hormones Page 1
Stability of Fagron's Phytobase Cream Compounded with Various Hormones Page 2
Stability of Fagron's Phytobase Cream Compounded with Various Hormones Page 3
Stability of Fagron's Phytobase Cream Compounded with Various Hormones Page 4
Stability of Fagron's Phytobase Cream Compounded with Various Hormones Page 5
Stability of Fagron's Phytobase Cream Compounded with Various Hormones Page 6
Stability of Fagron's Phytobase Cream Compounded with Various Hormones Page 7

Download in electronic PDF format for $75

Abstract:  The objective of this study was to evaluate the stability of 5 common hormones used as active pharmaceutical ingredients in Fagron Phytobase cream. The active pharmaceutical ingredients were tested using a bracketed format, as well as individually, and in one combination: estrone 0.1%, estrone 1%, estradiol 0.05%, estradiol 2%, estriol 0.05%, estriol 2%, progesterone 0.1%, progesterone 20%, testosterone 0.1%, testosterone 20%; combination (estradiol 0.05%, estriol 0.05%, progesterone 0.5%), and combination (estradiol 2%, estriol 1%, progesterone 20%). All creams were stored at controlled room temperature (20ÆC to 25ÆC) in a Topi-CLICK container-closure. Stability was assessed by measuring the percent recovery at varying time points throughout a 180-day period. Active pharmaceutical ingredients’ quantifications were performed by highperformance liquid chromatography via a stabilityindicating method. Antimicrobial effectiveness testing per United States Pharmacopeia Chapter <51> guidelines was carried out for each compounded formulation. Given the percent recovery of the active pharmaceutical ingredients within the cream base, the beyond-use date was determined to be 180 days in all samples except estrone, which was determined to be 150 days. This suggests that Phytobase cream is able to maintain the stability of various compounded hormones in the base over an extended time of storage.

Related Keywords: Tom Wynn, RPh, Sarah Taylor, PharmD, Clark Zander, Fagron Phytobase, hormone preparations, hormone replacement therapy, drug potency, estrone, estradiol, estriol, progesterone, testosterone, drug combinations, hormone concentration, antimicrobial effectiveness testing, United States Pharmacopeia Chapter <51>, beyond-use date, physical stability, chemical stability, microbial contamination, container closure integrity

Related Categories: EXCIPIENTS, HRT, PEER-REVIEWED, STABILITIES, COMPATIBILITIES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Stability of Fagron's Phytobase Cream Compounded with Various Hormones
Wynn Tom
, Taylor Sarah, Zander Clark
Mar/Apr 2021
Pg. 156-162

The Science Behind Hormone Replacement Therapy, Part 1
Wepfer Scott T
Nov/Dec 2001
Pg. 462-464

Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2
Ford Gina
, Garcia Lea
Jan/Feb 2001
Pg. 52-54

Bioidentical Hormone Replacement Therapy, Part 3, A Review of
Wepfer Scott T
Mar/Apr 2002
Pg. 142-146

Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens-Part 1
Ford Gina
, Garcia Lea
Nov/Dec 2000
Pg. 421-422

Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base
Polonini Hudson C
, Dijkers Eli, Ferreira Anderson O, Zander Clark, Taylor Sarah
Jul/Aug 2021
Pg. 336-343

Natural Progesterone in Natural Hormone Replacement Therapy, The Role of
Girouard Lorinda G
, Holm Richard C
May/Jun 2001
Pg. 218-220

Hormone Replacement Therapy: Part 1 - The Evolution of Hormone Treatment
Lorentzen Jean
Sep/Oct 2001
Pg. 336-338

Tri-Est, Progesterone, and Testosterone in Versatile, Phytobase, Fitaline, and HRT Supreme Cream Bases
Allen Loyd V Jr
May/Jun 2017
Pg. 238

Saliva Tests, Part 2: Salivary Hormones, Hormone Replacement Pharmacokinetics, and the Importance of Timely Testing
Kells John
, Dollbaum Charles M
Sep/Oct 2009
Pg. 392-399

Efficacy and Clinical Value of Commonly Compounded Hormone Replacement Therapy: A Literature Review
Beshay Sarah M
, Rivera Gerard, Balthasar Jan, Florea Naomi
Jan/Feb 2015
Pg. 6-12

A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1
Gillson George R
, Zava David T
Jul/Aug 2003
Pg. 250-256

The Value of Hormone Assessment
Collins Joseph J
Sep/Oct 2001
Pg. 342-344

The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States
Stephenson Kenna
, Jones William, Stephenson Douglas M M
May/Jun 2006
Pg. 175-183

Bioidentical Hormone Replacement Therapy, Part 2, A Review of
Wepfer Scott T
Jan/Feb 2002
Pg. 50-54

Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1
Deleruyelle Laura J
Sep/Oct 2016
Pg. 359-364

Hormone Therapy: It's Time for a Second Opinion
Collins Joseph J
, Ahlgrimm Maria
Mar/Apr 2008
Pg. 122-127

Bilateral Areolar Hyperpigmentation Following Transdermal Administration of Compounded Hormone Replacement Therapy
Griffee Chris
, Delano Amy
Mar/Apr 2012
Pg. 110-114

Compatibility of Various Hormones in Phytobase and HRT Heavy Cream Bases
Taylor Sarah
, Haselhorst Rodney
Jan/Feb 2024
Pg. 75-81

Satisfaction of Patients Using Bioidentical Hormones for Hormone Replacement Therapy
Santoro Filippo
Sep/Oct 2002
Pg. 378

Return to Top